The Cutting Edge and the Cutting Floor, Technology’s Dual Role in Health Research
From Stem Cell Therapy to AI-Generated X-rays, Recent Developments Highlight Both the Promise and the Peril of Technology in Medicine
The National Medical Commission has issued an advisory declaring stem cell therapy illegal for the treatment of Autism Spectrum Disorder in compliance with a Supreme Court order. The move is aimed at curbing illegal practices by private clinics in metropolitan and tier-2 cities that claim to treat autism and cerebral palsy using stem cell therapy, sources said. According to the advisory issued based on ICMR recommendations on Wednesday to all medical colleges, hospitals and registered medical practitioners, stem cell therapy can now be used only for 32 approved diseases.
This is not merely a regulatory clarification. It is a statement about the limits of medical innovation, the dangers of unregulated practice, and the responsibility of the state to protect vulnerable patients from exploitation. At the same time, other recent developments in health technology—from cloning research to AI-generated medical images—reveal a complex landscape where technology can both heal and harm, and where regulation must keep pace with innovation.
The Stem Cell Warning
Stem cell therapy has been one of the most hyped areas of medical research. The promise is extraordinary: cells that can regenerate damaged tissue, treat degenerative diseases, and perhaps even reverse conditions once thought incurable. But the gap between promise and reality is vast, and in that gap, unscrupulous practitioners have flourished.
Private clinics in metropolitan and tier-2 cities have been offering stem cell treatments for autism and cerebral palsy, conditions for which there is no proven stem cell therapy. Parents desperate for help for their children have paid large sums for treatments that offer no benefit and may cause harm. The NMC’s advisory, issued in compliance with a Supreme Court order, makes clear that such practices are illegal.
Stem cell therapy can now be used only for 32 approved diseases. This list includes conditions where the evidence base is established—certain blood disorders, some cancers, specific immune deficiencies. Autism and cerebral palsy are not on the list. The advisory is a reminder that medical innovation must be grounded in evidence, not hope.
The Limits of Cloning
Revealing the limitations of cloning, researchers who repeatedly cloned mice for two decades have discovered that such serial duplication triggers grave genetic mutations that accumulate over the generations and ultimately become fatal. A total of 1,206 cloned laboratory mice were generated from a single female donor mouse from 2005 to 2025 in research conducted in Japan. There were no outward signs of trouble through the first 25 generations, but mutations subsequently began piling up until becoming fatal. The 58th generation of the clones, burdened by mutations, died a few days after birth.
This research, while conducted on mice, has profound implications for our understanding of cloning and its limits. The technology of cloning—creating genetically identical copies of an organism—has been around since Dolly the sheep in 1996. But the Japanese research shows that even apparently successful cloning comes at a cost. The genetic integrity of cloned organisms degrades over successive generations, with mutations accumulating until the organism can no longer survive.
For the field of regenerative medicine, which sometimes uses cloning techniques, this research is a cautionary tale. The promise of cloning—creating replacement tissues or even organs—must be weighed against the biological reality that the cloning process itself introduces errors. The research does not make cloning impossible, but it suggests that the technology may have inherent limits that cannot be overcome.
Reducing Animal Testing
Britain’s medicines regulator said on Wednesday it will introduce a framework by the end of 2026, which would allow drug makers to ask a review of the data for drugs being developed without animal testing before applying for approval. The draft guidance from the United Kingdom’s Medicines and Healthcare products Regulatory Agency aims to reduce reliance on animal studies and aligns with a broader global push to limit such testing in drug development. The U.S. FDA too had issued draft guidance encouraging companies to reduce animal testing and adopt alternatives.
The move to reduce animal testing in drug development is part of a larger shift in the pharmaceutical industry. Animal testing has long been a standard part of drug development, required by regulators to demonstrate safety before human trials. But animal testing is expensive, time-consuming, and ethically problematic. It also does not always predict human responses accurately.
New technologies—organ-on-a-chip systems, computer modeling, and advanced cell cultures—offer alternatives to animal testing. The UK and US regulators are now creating pathways for drug makers to use these alternatives. The shift is gradual, but it is significant. It reflects a recognition that the future of drug development will rely less on animals and more on advanced in vitro and in silico models.
The AI-Generated X-Ray Problem
Fake X-ray images created by artificial intelligence tools to resemble true results from human patients can fool not only experienced radiologists but also the artificial intelligence tools themselves, according to a study. The study illustrates the potential for manipulation by bad actors. Seventeen radiologists from 12 hospitals in six countries reviewed 264 X-ray images, half of which had been generated by the artificial intelligence tools including ChatGPT or RoentGen. When radiologist readers were unaware of the study’s true purpose, only 41 per cent spontaneously identified AI-generated images, according to a report.
This finding is alarming. AI-generated medical images are now sophisticated enough to fool both human experts and the AI tools designed to detect fraud. The implications for medical fraud are obvious: fake X-rays could be used to support false insurance claims, to fabricate medical histories, or to create false evidence in legal cases.
But the implications go deeper. If AI-generated images are indistinguishable from real ones, then the entire edifice of medical imaging—a cornerstone of modern diagnosis—becomes vulnerable. Radiologists rely on the authenticity of the images they interpret. If they cannot trust what they see, the diagnostic process breaks down.
The study also raises questions about the training of AI tools. If AI models are trained on data that includes AI-generated images, they may learn to recognize patterns that are not real, further blurring the line between authentic and artificial. The problem is not theoretical; it is already happening.
The Common Thread
These four stories—stem cell regulation, cloning research, animal testing alternatives, and AI-generated X-rays—may seem unrelated. But they share a common theme: the tension between technological possibility and responsible use.
In each case, technology offers new possibilities. Stem cells could regenerate damaged tissue. Cloning could create replacement organs. AI could enhance medical imaging. New in vitro models could replace animal testing. But each possibility comes with risks. Stem cell treatments offered by unscrupulous clinics can harm patients. Cloning can introduce fatal genetic mutations. AI-generated images can be used to commit fraud. Even well-intentioned alternatives to animal testing must be validated before they can be trusted.
The role of regulation is to manage these risks without stifling innovation. The NMC’s stem cell advisory is an example of regulation that protects patients from exploitation while allowing legitimate research to continue. The UK and US moves to reduce animal testing are examples of regulation that adapts to new technologies. The research on cloning and on AI-generated images is a reminder that even the most promising technologies have limits and dangers.
The Path Forward
As technology continues to advance, the challenges will only grow. AI will become more sophisticated, and with it, the potential for manipulation. Stem cell research will continue, and with it, the temptation to offer unproven treatments. Cloning may find new applications, and with them, new ethical dilemmas.
The response must be vigilant. Regulators must stay ahead of the technology, anticipating risks before they become crises. Researchers must be transparent about the limitations of their work, not just its promise. Clinicians must be guided by evidence, not hope. And patients must be protected from exploitation.
The four stories from this week are snapshots of a larger reality: technology is transforming medicine, but it is not a magic wand. It must be used with care, regulated with wisdom, and guided by the fundamental principle that the patient’s welfare comes first.
Q&A: Unpacking Technology’s Role in Health Research
Q1: What has the National Medical Commission said about stem cell therapy for autism?
A: The NMC has issued an advisory declaring stem cell therapy illegal for the treatment of Autism Spectrum Disorder, in compliance with a Supreme Court order. Stem cell therapy can now be used only for 32 approved diseases. The move aims to curb illegal practices by private clinics in metropolitan and tier-2 cities that claim to treat autism and cerebral palsy using unproven stem cell therapies, which can cause harm and exploit desperate families.
Q2: What did the Japanese cloning research reveal about genetic mutations?
A: Researchers who cloned mice over two decades discovered that serial cloning triggers grave genetic mutations that accumulate over generations and ultimately become fatal. Of 1,206 cloned mice generated from a single female donor between 2005 and 2025, there were no outward signs of trouble through the first 25 generations, but mutations then began piling up. The 58th generation died a few days after birth. The research highlights inherent limits of cloning technology.
Q3: What changes are being made to reduce animal testing in drug development?
A: Britain’s medicines regulator will introduce a framework by end of 2026 allowing drug makers to seek review of data for drugs developed without animal testing before applying for approval. The U.S. FDA has also issued draft guidance encouraging reduced animal testing. The shift aligns with a broader global push to adopt alternatives like organ-on-a-chip systems, computer modeling, and advanced cell cultures, which are more ethical and sometimes more predictive of human responses.
Q4: How effective are AI-generated X-rays at fooling radiologists?
A: A study found that AI-generated X-ray images can fool both experienced radiologists and AI detection tools. Seventeen radiologists from 12 hospitals in six countries reviewed 264 X-ray images, half AI-generated using tools like ChatGPT or RoentGen. When radiologists were unaware of the study’s purpose, only 41% spontaneously identified AI-generated images. This raises serious concerns about potential fraud, manipulation of medical records, and erosion of trust in medical imaging.
Q5: What common theme connects these four health technology stories?
A: All four stories illustrate the tension between technological possibility and responsible use. Stem cells, cloning, AI, and alternatives to animal testing each offer great promise, but each also carries risks: unproven treatments can harm patients; cloning can introduce fatal mutations; AI-generated images can enable fraud; and even well-intentioned alternatives must be validated before use. The role of regulation is to manage these risks without stifling innovation, protecting patients while allowing legitimate research to proceed. The stories underscore that technology is not a magic wand—it must be used with care, regulated with wisdom, and guided by patient welfare.
